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The primary aim of this study was to investigate if the expression of the DNA damage identifying protein DNA-PKcs known to be
involved in DNA repair after treatment with ionising radiation can be used as a predictive marker for radiotherapy (RT) response in
cervical cancer. Formalin-fixed primary tumour biopsies from 109 patients with cervical cancer, FIGO-stage IB–IIA, treated with
preoperative brachytherapy followed by radical surgery were analysed by immunohistochemistry. In addition, correlation studies
between early pathological tumour response to radiation and expression of Ku86, Ku70, Mdm-2, p53 and p21 in primary tumours
were also performed. We found that tumour-transformed tissue shows positive immunostaining of DNA-PKcs, Ku86 and Ku70, while
non-neoplastic squamous epithelium and tumour-free cervix glands show negative immunoreactivity. Expression of DNA-PKcs
positively correlated with both Ku86 and Ku70, and a statistically significant correlation between the Ku subunits was also found. After
RT, 85 patients demonstrated pathologic complete remission (pCR), whereas 24 patients had residual tumour in the surgical
specimen (non-pCR). The main finding of our study is that there was no correlation between the outcome of RT and the expression
of DNA-PK subunits. Positive p53 tumours were significantly more common among non-pCR cases than in patients with pCR
(P¼0.031). Expression of p21 and Mdm-2 did not correlate with the outcome of RT.
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Early stage cervical cancer can be successfully treated by radio-
therapy (RT). We have shown that pathologic complete remission
(pCR) after preoperative brachytherapy as compared to incom-
plete pathologic remission (non-pCR) is a strong predictive factor
for long-term survival (Beskow et al, 2002).
The primary action of ionising radiation is to produce DNA
damage, leading to cell death. At the cellular level, DNA double
strand breaks (DSBs) are considered as the most lethal lesions and
sensitivity to ionising radiation will depend on the DSB repair
efficacy possessed by the cell. Nonhomologous end joining (NHEJ)
is a major pathway for repair of DNA DSBs in mammalian cells
(Hefferin and Tomkinson, 2005). The initial step of NHEJ involves
binding of the DNA-dependent protein kinase, DNA-PK, which
holds the ends to be joined in physical proximity, permitting
modifications of the broken ends to make them compatible before
ligation (DeFazio et al, 2002). DNA-PK is composed of a 465kDa
catalytic subunit, DNA-PKcs, and a heterodimer of Ku86 and
Ku70, which acts as a DNA targeting and regulatory component of
the complex (Mimori and Hardin, 1986; Dynan and Yoo, 1998).
DNA-PKcs is a serine/threonine protein kinase belonging to the
phosphatidylinositol-3 kinase-related kinase family, which include
other large proteins involved in DNA repair signalling, such as
ATM and ATR (Shiloh, 2003). Genetic mutations in the ATM or
DNA-PKcs gene result in immunodeficiency, cancer susceptibility
and hypersensitivity to ionising radiation (Lavin and Shiloh, 1997;
Rotman and Shiloh, 1999). However, in contrast to ATM, DNA-
PKcs deficiency has not been described in humans, as in lower
species (Blunt et al, 1995; Wiler et al, 1995; Shin et al, 1997; Meek
et al, 2001; Ding et al, 2002). In human tumour cell lines of
glioblastoma origin DNA-PKcs has been shown to be important for
their response to radiation (Allalunis-Turner et al, 1993). Also in
lung cancer cell lines a correlation between content of DNA-PKcs
and radiation sensitivity has been demonstrated (Sirzen et al,
1999). The primary aim of our study was to evaluate a possible role
between the frequency of tumour cells in cervical cancer staining
positively for DNA-PKcs and tumour response to RT. As a
deficiency in Ku86 or Ku70 also has been shown to confer
increased sensitivity to ionising radiation (Taccioli et al, 1994;
Jeggo et al, 1995), parallel staining for these two subunits of DNA-
PK was performed as part of secondary aims.
Also proteins downstream of DNA-PK would be of potential
interest to evaluate in the same direction. DNA-PK has been shown
to phosphorylate several nuclear DNA-binding proteins in vitro,
including the transactivation domain of p53 (Lees-Miller et al,
1992). The tumour suppressor gene p53 plays a critical role in the
cellular response to ionising radiation (Kastan et al, 1991). One of
the results of p53 activation is p21 synthesis and accumulation,
eventually causing G1 arrest (el-Deiry et al, 1993; Harper et al,
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s1993). If the DNA repair enzymes succeed in repairing the DNA
DSBs, activation of p53 ceases, p21 is degraded and the cell is then
free to proceed through the cell cycle. If the DNA repair machinery
fails, activated p53 can drive the cell to apoptosis (Vousden, 2000).
Regulation of p53 is partially carried out by Mdm-2, which binds
to p53 and thereby renders it both inactive and available for
degradation (Unger et al, 1999). Phosphorylation of p53 leads to
release from Mdm-2 control and makes p53 transcriptionally
active (Shieh et al, 1997). In addition, disassociation between p53
and Mdm-2 may be achieved by phosphorylation of Mdm-2 and
previously, it was demonstrated that DNA-PK can phosphorylate
Mdm-2, rendering Mdm-2 unable to inhibit p53 transactivation
(Mayo et al, 1997). When DNA repair is accomplished, DNA-PK
activity is abolished, resulting in newly synthesised Mdm-2 protein
that is unphosphorylated and capable of binding p53, allowing cell
cycle progression.
In carcinoma of the cervix, there are indications pointing to
intrinsic radiosensitivity of the tumour as a determinant of
outcome following RT (West et al, 1997). The possibility to
measure radiosensitivity in the primary tumour would be of great
importance when deciding optimal treatment regimen for the
individual patient.
In the present study, we analysed primary tumour biopsies from
patients with cervical cancer, treated with preoperative brachyther-
apy followed by surgery. In addition to our primary goal to assess
for a relation between DNA-PKcs and response to RT as secondary
goals the expression of Ku86, Ku70, Mdm-2, p53 and p21 were
analysed for their impact on response to RT. To assess protein
expression we used immunohistochemistry (IHC) staining provid-
ing us with a frequency of stained tumour cells for each case
analysed. These data were correlated with treatment response
defined as pathological complete tumour remission after RT.
MATERIALS AND METHODS
Sample size determination
Our primary end point was pathological complete tumour
remission. Our hypothesis was that low percentage immunostain-
ing (below the median) of DNA-PKcs in primary tumour would
result in pCR after RT to a greater extent than high (above the
median) immunopositivity of DNA-PKcs. Our null hypothesis was
that no difference in pathological complete tumour remission
prevailed in that respect. If the patients with low DNA-PKcs
showed a rate of complete pathological tumour remission of 45%
and the ‘high’ group had 20% complete tumour remission we
should need 2 43¼86 patients to detect that difference. This is
true if the significant level is 5%, the power is 80% and with a one
sided hypothesis.
Patients
Pretreatment biopsy specimens were obtained from 109 patients
with cervical carcinoma FIGO stage IB-IIA, treated at the
Department of Gynaecologic oncology, Radiumhemmet, during
January 1989 to December 1991. Age at time of diagnosis varied
between 23 and 75 years, with a mean age of 44 years. Median
follow-up for patients alive and not alive were 69 months (range
50–109 months) and 19 months (range 0–87 months), respec-
tively. There were 25 patients with small tumours (o2cm), 47
patients with large tumours (X4cm) and 37 patients had tumours
of intermediate size (2–o4cm). Tumour characteristics, such as
stage distribution, tumour size, histopathological type and grade
in relation to the degree of tumour remission after RT is shown
in Table 1. Preoperative treatment included two uterovaginal
insertions with a 3-week interval. Surgery according to the
Wertheim–Meig procedure was performed 4 weeks after the
second insertion. Brachytherapy was given according to the
‘Stockholm method’, described elsewhere (Beskow et al, 2002).
The remote after-loading technique with caesium was used in 69
patients giving a mean total dose of 43Gy and a mean dose rate to
point A of 1.35Gyh
 1. In all, 40 patients were treated with the
manual technique using radium applicators with a calculated total
uterovaginal mean dose of 6500 milligram-hours of radium
(mghRa) and a retrospectively estimated dose rate to point A of
1.1Gyh
 1. Tumour response did not differ significantly between
the two techniques. The use of biopsies and surgical specimens for
the present study was approved by the Ethics Committee at the
Karolinska Institute. Informed consent were received from all
patients alive at time of analysis.
Assessment of early pathological response
Evaluation of RT response was performed by histopathological
examination of the formalin-fixed surgical specimen within 1 week
after surgery. All specimens were re-evaluated by a senior
pathologist. Tumour remission was assessed in the surgical
specimen and was classified as pCR if no morphological intact
tumour cells were found or as non-pCR if residual tumour was
detected.
Immunohistochemistry
Immunostaining was preformed using the ABC-technique (Vector
Laboratories, Elite Standard Kit. Cat. PK-6100, Burlingame, CA,
USA). Paraffin sections (4mm), placed on Super Frost Plus slides,
were dewaxed and rehydrated. The slides were boiled in citrate
buffer pH 6.0, in a microwave oven for 12min at 800W and 20min
at 250W. The slides were then cooled and rinsed with phosphate
buffer saline (PBS). After blocking with 1% BSA, the proteins were
detected by using mouse monoclonal antibodies to DNA-PKcs
1:100, Ku86 1:200, Ku70 1:200 (Neo Markers, Union City, CA,
USA), p53 1:100 (clone DO-7, DAKO, Kyoto, Japan), p21 1:50
(clone EA10, Oncogene research products, Cambridge, MA, USA),
and Mdm-2 at 1:50 (SMP14, Santa Cruz Biotechnology, Santa
Cruz, CA, USA). The protein primary antibody was then detected
by incubation with a biotinylated secondary antibody and ABC
Table 1 Tumour characteristics in relation to tumour remission
Parameter
Pathological
complete
remission
(pCR)
Incomplete
pathological
remission
(non-pCR)
Total no. of
patients P-value
No. of patients 85 (78%) 24 (22%) 109
FIGO stage
IB 69 (81%) 16 (19%) 85 P¼0.130
a
IIA 16 (67%) 8 (33%) 24
Tumour size
o 2cm 24 (96%) 1 (4%) 25
2- o4cm 32 (86%) 5 (14%) 37 Po0.001
b
X4cm 29 (62%) 18 (38%) 47
Histologic type
Squamous 61 (79%) 16 (21%) 77
Adeno 19 (73%) 7 (27%) 26 P¼0.628
a
Adenosquamous 5 (83%) 1 (17%) 6
Grade of differentiation
Well 9 (69%) 4 (31%) 13
Moderate 44 (83%) 9 (17%) 53 P¼0.391
a
Poor 27 (73%) 10 (27%) 37
Unspecified 5 (83%) 1 (17%) 6
aw
2 test.
bw
2 test for trend.
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scomplex (Vector Laboratories), using diaminobenzedine substrate
as a chromogene. The specimens were counterstained with
haematoxylin. Staining evaluation was performed in a blinded
fashion, without prior knowledge of the clinical data or outcome
for the individual patient. Counting was carried out on four
representative areas in a light microscope. In every specimen 500
tumour cells were counted and the percentage of positive stained
cells was determined. Intensity of immunostaining was judged as
low, intermediate or strong. Morphologically normal cells in each
specimen served as internal negative control. The intraobserver
reproducibility was tested and showed significant correlation
between the two series of evaluations (r¼0.95, Po0.001).
Statistical analysis
Statistical tests on data were based on w
2. When comparison
between high and low protein expression was assessed, a high
protein level was defined as a percentage of stained cells above the
median value and a low protein level was defined as a percentage
of stained cells below the median value. Correlation coefficient of
Spearman (rs) was calculated to compare expression of proteins.
Survival analyses on continuous background factors were calcu-
lated by Cox regression bivariate analysis.
Pearson correlation test was used to test intraobserver variation.
RESULTS
DNA damage response proteins in cervical carcinoma
Immunostaining was performed on formalin-fixed biopsies against
DNA-PKcs (Figure 1A–D), Ku86 (Figure 1E) and Ku70
(Figure 1F). Non-neoplastic squamous epithelium and tumour-
free cervical glands were negative for all of the DNA-PK subunits.
In tumour-transformed tissue, nuclear staining of DNA-PKcs
could be detected in all of the 109 tumours analysed. The
percentage of DNA-PKcs positive cells within a tumour sample
varied between 20 and 100%, with a median of 66%. DNA-PKcs
was expressed with varying intensity between tumour samples. The
majority of the samples were intermediately or strongly positive
Figure 1 Immunohistochemical analysis of DNA-PKcs, Ku86 and Ku70 in samples from patients with cervical carcinoma. (A) Non-neoplastic squamous
epithelium negative for DNA-PKcs protein. (B) Ordinary cervix gland negative for DNA-PKcs, with positively stained lymphocytes in the adjacent tissue,
indicated with arrows. (C) Positive DNA-PKcs protein expression in partly poorly differentiated adenocarcinoma. The surrounding non-neoplastic tissue
demonstrates lack of immunoreactivity concerning DNA-PKcs. (D) Positive expression of DNA-PKcs in squamous cell carcinoma. (E) Poorly differentiated
squamous cell carcinoma as demonstrated by a Ku86 staining present in the tumour. Negatively stained granulocytes are indicated with arrows. (F) Nuclear
staining of Ku70 protein in well-differentiated adenocarcinoma. Majority of cells are positively stained with high intensity. Inflammatory cell reaction with small
lymphocytes expressing Ku70 (arrow).
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sfor DNA-PKcs. In 10 samples the intensity was judged as low. No
significant difference in expression of DNA-PK between small/
intermediate and large tumours were found. Staining for Ku86 was
found in 107 cases and the percentage of positive cells varied
between 24 and 100%, with a median of 74%. Expression of
Ku70 was detected in all but one of the tumours analysed. The
percentage immunopositive cells ranged from 15 to 99%, with a
median of 78%. For both Ku86 and Ku70 the immunostaining were
localised to the nucleus and the intensity of staining were judged
as strong. When comparing small/intermediate and large tumours
no significant difference in expression of neither Ku70 nor Ku86
could be found. DNA-PKcs positivity was found to correlate with
Ku86 positivity (rs¼0.49, Po0.001) as well as with Ku70 positivity
(rs¼0.53, Po0.001). In addition, a correlation between the Ku
subunits (rs¼0.50, Po0.001) was found.
Mdm-2, p53 and p21 were also assessed for on formalin-fixed
primary tumour tissue. Immunostaining of Mdm-2 varied
considerably between the tumours. Nine of the samples showed
no staining for Mdm-2 protein. The percentage of Mdm-2 positive
cells varied between 10 and 100% with a median value of 68%. In
all, 59 cases displayed nuclear staining, while in 41 of the tumours
Mdm-2 could only be detected in the cytoplasm. Intensity of
staining was intermediate or low in 40 and 36 cases, respectively,
whereas 24 cases were strongly positive for Mdm-2 protein.
Immunopositivity for p53 was found in 38 of the tumours analysed
and the percentage of stained cells ranged from 5 to 33%. The
median value was 0 due to the high percentage of p53 negativity.
Staining was nuclear, of intermediate or high intensity. Immuno-
positivity for p21 was found in 73 cases and the percentage stained
cells ranged from 5 to 66% with a median value of 15 %. A positive
correlation was found between protein expression of p53 and p21
(rs¼0.27, P¼0.005) as well as between p53 and Mdm-2 (rs¼0.27,
P¼0.004) When the frequency of p53 positivity was compared
between small/intermediate tumours and large tumours, the
amount of cells staining positive for p53 was found to be
significantly higher in large tumours (P¼0.018). In addition, a
positive correlation between tumour size and immunopositivity
for p21 was also found (P¼0.002). No correlation could, however,
be found between tumour size and high and low expression of
Mdm-2. p53-positive tumours showed a significantly higher
expression of DNA-PKcs than p53-negative tumours (P¼0.009).
No significant difference in protein expression was detected
between the different histogenetic types of cervical carcinoma. In
addition, differences in protein expression between grades of
differentiation could not be found. No correlation was found
between long-term survival and expression of any of the analysed
proteins (Tables 2 and 3).
RT-induced remission and expression of DNA damage-
related proteins
With an attempt to identify predictive markers for radiosensitivity,
we assessed for correlations between protein expression in primary
tumour and treatment outcome assessed in the surgical specimen.
Comparison between pCR and non-pCR with respect to expression
of DNA-PKcs, Ku86 and Ku70 were based on samples with low
percentage stained cells (omedian value) or high percentage
stained cells (4median value). We could not detect any significant
difference in protein expression of DNA-PKcs in primary tumour
between pCR and non-pCR cases. In addition there were no
significant difference in protein expression of the subunits Ku70
and Ku86 between pCR and non-pCR cases (Figure 2). Comparison
between samples with high and low expression revealed that
neither Mdm-2, nor p21 can be used as markers of early
pathological response after RT in early stages of cervical carcinoma
(Figure 3). There was no significant difference between nuclear and
cytoplasmic Mdm-2 staining with respect to early pathological
response. We found that positive p53 tumours were significantly
more common among non-pCR cases compared with patients
showing pCR (P¼0.031) (Table 4). Differences in intensity of
staining could not be detected for any of the analysed proteins
when comparing pCR and non-pCR samples.
Table 2 Protein expression in primary tumour with respect to survival
Factor RH CI P-value
DNA-PKcs 0.995 0.975–1.015 0.606
Ku70 0.994 0.973–1.015 0.564
Ku86 0.999 0.981–1.018 0.948
Mdm2 1.004 0.990–1.017 0.599
p21 1.012 0.987–1.038 0.362
RH¼relative hazard; CI¼95% confidence interval.
Table 3 Survival and expression of p53 in primary tumour
No. of patients Deaths % P-value
p53
0 71 11 15.5 0.157
1 38 10 26.3
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Figure 2 Expression of DNA-PKcs (triangles), Ku86 (circles) and Ku70
(squares) in primary biopsies from patients with cervical carcinoma and
comparison between pCR (filled symbols) and non-pCR cases (unfilled
symbols). Median values are indicated. NS (Mann–Whitney Test).
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Figure 3 Expression of p21 (triangles) and Mdm-2 (circles) in primary
biopsies from patients with cervical carcinoma and comparison between
pCR (filled symbols) and non-pCR cases (unfilled symbols). Median values
are indicated. NS (Mann–Whitney Test).
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sDISCUSSION
The aim of our study was to see if there is a relation between DNA-
PKcs and response to RT in homogenously treated cervical
carcinoma of stage IB-IIA as assessed by IHC in the primary
tumour. We were, however, not able to demonstrate such a
correlation. In addition, related proteins as Ku70 and Ku86 also
did not correlate with RT response. Among down streams effectors
analysed like Mdm-2, p53 and p21 only the frequency of IHC
determined p53-positive cells showed a statistically significant
correlation with response to RT measured as pathological
complete tumour response.
When assessing DNA-PK protein expression in primary tumour
biopsies from patients with cervical carcinoma, we found non-
neoplastic tissue including non-neoplastic squamous epithelium
and connective tissue to express no or very low DNA-PKcs, Ku86
and Ku70. In tumour-transformed tissue in both squamous cell
carcinoma and adenocarcinoma, on the other hand, positive
immunostaining was found for all three proteins but to a variable
extent. This is in agreement with other studies, in which DNA-
PKcs, Ku86 and Ku70 were found to be upregulated in tumour
tissue from bladder and colorectal carcinoma, as compared with
the corresponding non-tumour tissue (Stronati et al, 2001; Hosoi
et al, 2004). It has also been shown that DNA damage response
proteins, such as ATM, Chk2, p53 and g-H2AX are constitutively
activated and expressed at higher levels during early tumorigenesis
as compared to normal tissue (Bartkova et al, 2005).
The absence of a correlation between IHC measured expression
of DNA-PK and tumour response is at some variance with other
reports indicating a positive role of DNA-PK as a predictive
marker for radiosensitivity in cervical carcinoma. In a study by
Wilson et al (2000) including patients with cervical carcinoma
stage I–III, all tumours with a low frequency of Ku70 or Ku80
immunopositive cells (o60%) were radiosensitive in a clonogenic
assay. There was, however, no overall statistically significant
correlation between in vitro radiosensitivity (SF2-values) of
explanted tumour cells and expression of Ku70 or Ku80 in
primary biopsies. A significant higher survival rate was found for
patients whose tumours had a low level of Ku70 expression but no
relation was found with low Ku80 expression. In contrast to
Wilson’s study, our study only included patients with early stages
(IB–IIA) of cervical carcinoma. We did not find a correlation
between DNA-PKcs and their subunits with response to RT. In
addition, we did not find a correlation between expression in
primary tumour biopsies and long-term survival for any of the
studied proteins.
Differences in patient populations concerning tumour stages
may be of importance for diverging results since it is not clear if
or how the molecular pattern in tumours changes with progressive
disease. In addition, the definition of response to RT differs
between studies. As surgery was included in the treatment
schedule in our study we based the definition of treatment
response on the pathological evaluation of the whole cervix.
Defining response to RT in the individual patient by in vitro
methods such as soft agar clonogenic assay could be questioned
since methodological factors may have a considerable effect on the
SF2-values of explanted tumour cells which has to be accounted for
when the results are interpreted. Using survival as an end point
when evaluating molecular factors of importance for clinical
response to RT, also has drawbacks. Survival is a variable
that strongly is affected by tumour stage, age, performance status,
intercurrent diseases and all treatment given to the patient. The
comparison of tumour response to expression of DNA-PK seems
less biased.
Harima et al (2003) reports significantly better clinical response
to RT among Ku80-negative tumours, assessed by IHC on primary
biopsies, as compared to Ku80-positive tumours. Furthermore,
patients with Ku80-negative tumours were also found to have
better survival than those with Ku80-positive tumours. The study
included patients with microinvasive disease (FIGO stage IA) as
well as patients with advanced disease and distant metastases
(FIGO stage IVB) and clinical response and survival was used as a
measure of radiosensitivity. Clinical response used as an end point
for analysing the importance of molecular markers for treatment
response can be problematic. This is especially apparent when the
studied patients are heterogeneous with respect to tumour stage.
Clinical response is primarily based on physical and radiological
examinations, and time of evaluation, experience of the clinician as
well as the type and quality of performed radiology are factors that
will influence the judgement. Harima’s study differed from ours
with respect to mean age of the patient population (65 vs 44 in our
study) and also by that a major part of patients presented more
advanced stages (stage III–IV). A radioresistant phenotype of a
tumour may originate from a small population of cells possessing
the prerequisite for survival after irradiation, indicating that
heterogeneity of level of protein expression on the cellular level
may be of importance when searching for markers that can predict
tumour response. In the Harima study the IHC scoring system
differs from ours with the inclusion of staining density, a
parameter which we have left out. In our study, no differences
in intensity of staining could be detected for any of the analysed
proteins when comparing pCR and non-pCR samples.
When assessing molecular factors important for response of
tumours to RT it is important to consider the impact of FIGO-stage
and tumour size (Eifel et al, 1994; Perez et al, 1998). We previously
showed that small tumours more often reach complete remission
following brachytherapy as compared with large tumours (Beskow
et al, 2002). This may reflect difficulties in dose planning and
targeting large tumour volumes. However, one may hypothesise
that large tumours may have a different molecular pattern that
could be of importance for the response to radiation. There are
clinical studies on DNA-PK and outcome of RT on other tumour
sites with diverging results. In head and neck cancer there are
reports of no correlation between expression of DNA-PKcs and
the subunits Ku70/Ku86 and in vitro radiosensitivity of explanted
tumours (Bjo ¨rk-Eriksson et al, 1999), while in another study
tumours with high levels of Ku86 displayed better locoregional
control after RT as compared with tumours expressing low levels
of Ku86 (Friesland et al, 2003). In a study of patients with rectal
carcinoma treated with preoperative RT, low levels of Ku70
immunostaining was related to radiosensitivity (Komuro et al,
2003). It is known that deficiency in any of the DNA-PK subunits
leads to impaired DNA DSB repair and increased sensitivity to
ionising radiation (Taccioli et al, 1994; Jeggo et al, 1995;
Kirchgessner et al, 1995). Also, activity and DNA-PK expression
has been shown to correlate with radiosensitivity in both lung
cancer cell lines (Sirze ´n et al, 1999) and oesophageal cancer cell
lines (Zhao et al, 2000). However, the significance of DNA-PK in
biopsy specimen as a predictive indicator of radiosensitivity is
clearly not as obvious. A possible explanation for this diversity
could be the heterogeneity of a tumour as compared to cell lines.
Other factors of importance may be the surrounding tissue of a
tumour, which may influence the tumour response to treatment, or
the degree of hypoxia. One also has to consider the possibility that
Table 4 Staining of p53 in primary biopsies in relation to radiation
response
p53 negative p53 positive No. of patients P
a
pCR
b 60 (71%) 25 (29%) 85 (100%)
non-pCR
c 11 (46%) 13 (55%) 24 (100%) 0.031
Total 71 38 109
aP¼statistical significance using w
2 test.
bpCR¼pathological complete remission.
cnon-pCR¼incomplete pathological remission.
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snon-pCR cases represent a group of cases that vary in sensitivity to
RT since we were not able to assess the exact decrease of tumour
mass but just divide the material in pCR and non-pCR. The total
overlap between the groups as regards IHC positivity, however,
argues against such an explanation for the lack of difference
between the pCR and non-pCR groups.
Prognostic significance for p53 immunostaining has previously
been evaluated for RT in patients with cervical carcinoma (Ebara
et al, 1996; Mukherjee et al, 2001). In primary biopsies from
patients with advanced cervical carcinoma, p53 protein expression
was not found to correlate with treatment outcome (Ebara et al,
1996). We did, however, find that primary tumour biopsies
staining positive for p53 will confer non-pCR, which is in
agreement with the findings by (Mukherjee et al, 2001). In cervical
carcinoma, there are two different mechanisms that may explain
the loss of p53 function: a somatic gene mutation, which leads to
an inactive form, and the enhanced protein degradation promoted
by the E6 oncoprotein of the human papilloma virus types (HPV)
16 and 18 (Scheffner et al, 1990). In contrast to many other human
tumour forms, p53 mutations are only rarely detected in cervical
carcinoma (Benjamin et al, 1996). In our study, we do not know if
the E6-mediated pathway is responsible for the detected correla-
tion between p53 positivity and lack of tumour response to RT.
There is, however, evidence showing that expression of p53 does
not differ between HPV-positive and -negative cervical cancers
(Troncone et al, 1998). On the other hand, it is difficult to conclude
that mutant p53 is the underlying cause of radioresistance in
cervical carcinoma. The p53 antibody used in this study reacts with
an epitope in the N-terminus of both wild and mutant types of p53
protein localised in the cell nucleus. Also, it has been shown that
p53 mutation and immunoreactivity, cannot be correlated in
cervical carcinoma, which is in contrast to mammary and
endometrial cancer (Schneider et al, 1994).
In conclusion, results of the present study suggest a role for
DNA-PK in tumour transformation since elevated levels of DNA-
PKcs, Ku86 and Ku70 were found in tumour tissue as compared
with non-neoplastic tissue. Our results, however, imply that
immunohistochemical assessment of the DNA-PK complex cannot
be used as a predictive marker for clinical response to brachy-
therapy of early stages of cervical carcinoma. However, expression
of p53 protein is more frequent among cases with incomplete
pathological remission after brachytherapy of cervical carcinoma.
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